Stay updated on Nivolumab vs Cabiralizumab in T Cell Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Cabiralizumab in T Cell Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Cabiralizumab in T Cell Lymphoma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The site’s displayed release/revision version was updated from v3.5.2 to v3.5.3, with no change to the study record content.
    Difference
    0.1%
    Check dated 2026-04-24T17:14:25.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2. This appears to be a minor version update without visible changes to content or user-facing features.
    Difference
    0.1%
    Check dated 2026-04-17T13:52:02.000Z thumbnail image
  4. Check
    29 days ago
    No Change Detected
  5. Check
    50 days ago
    Change Detected
    Summary
    Revision: v3.5.0 has been added and Revision: v3.4.3 has been removed.
    Difference
    0.1%
    Check dated 2026-03-19T23:45:46.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3. This change does not alter any study data, eligibility criteria, or outcomes.
    Difference
    0.1%
    Check dated 2026-03-12T19:41:57.000Z thumbnail image
  7. Check
    86 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2 on the page.
    Difference
    0.1%
    Check dated 2026-02-12T01:46:39.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1.
    Difference
    0.1%
    Check dated 2026-02-04T23:44:25.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Cabiralizumab in T Cell Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Cabiralizumab in T Cell Lymphoma Clinical Trial page.